证券代码：002432 证券简称：九安医疗 公告编号：2025-054 天津九安医疗电子股份有限公司 关于中期票据和超短期融资券获准注册的公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）于2025年6月3日召开 第六届董事会第二十三次会议、第六届监事会第十八次会议，审议通过了《关于 拟注册和发行中期票据及超短期融资券的议案》。同意公司向中国银行间市场交 易商协会（以下简称"交易商协会"）申请注册发行总额不超过人民币35亿元（含 35亿元）的中期票据和不超过人民币5亿元（含5亿元）的超短期融资券。具体内 容详见2025年6月5日，公司于《证券时报》、巨潮资讯网（www.cninfo.com.cn） 披露的相关公告。 公司于近日分别收到交易商协会出具的《接受注册通知书》（中市协注〔2025〕 MTN749号和中市协注〔2025〕SCP207号），交易商协会决定接受公司科技创新 债券注册。主要内容如下： 一、公司中期票据注册金额为35亿元，注册额度自《接受注册通知书》（中 市协注〔2025〕MTN749号）落款之 ...

Group 1 - The stock price of Jiuan Medical reached 39.68 yuan as of August 7, 2025, reflecting a 1.82% increase from the previous trading day [1] - The company reported a revenue of 62.95 million yuan from its new retail business in 2024, accounting for approximately 2.4% of total revenue [1] - Jiuan Medical expects a net profit attributable to shareholders of 880 million to 980 million yuan for the first half of 2025, representing a year-on-year growth of 46.24% to 62.86% [1] Group 2 - The main source of profit growth is attributed to the strong performance of asset management business in large asset allocation [1] - On August 7, the net inflow of main funds was 59.65 million yuan, accounting for 0.34% of the circulating market value [1] - Over the past five days, the net outflow of main funds was 4.21 million yuan, representing 0.02% of the circulating market value [1]

Group 1 - The core viewpoint of the news is that Jiuan Medical's stock performance shows a significant decline in its price-to-earnings (PE) ratio, indicating potential undervaluation compared to the industry average [1] - As of August 7, Jiuan Medical's closing price was 39.68 yuan, with a PE ratio of 11.15, which is the lowest in 59 days, and a total market capitalization of 18.819 billion yuan [1] - The average PE ratio for the medical device industry is 54.79, with a median of 37.86, positioning Jiuan Medical at the 32nd rank within the industry [1] Group 2 - On August 7, Jiuan Medical experienced a net inflow of main funds amounting to 59.653 million yuan, although it has seen an overall outflow of 4.2055 million yuan over the past five days [1] - The company's main business includes the research, production, and sales of home medical devices, with key products being the iHealth series, non-self-branded products, traditional hardware products, and internet medical products [1] - In the latest quarterly report for Q1 2025, Jiuan Medical reported a revenue of 507 million yuan, a year-on-year decrease of 33.49%, while net profit was 266 million yuan, reflecting a year-on-year increase of 7.62%, with a gross profit margin of 70.46% [1]

| 601298 | 青岛港 | 1.82 | 0.31 | 8.86 | 8.95 | 1.01 | | --- | --- | --- | --- | --- | --- | --- | | 300782 | 卓胜微 | 2.88 | 3.82 | 77.15 | 77.90 | 0.98 | | 600368 | 五洲交 | 1.39 | 2.44 | 4.35 | 4.39 | 0.91 | | | 通 | | | | | | | 872808 | 曙光数 | 1.02 | 2.07 | 61.05 | 61.60 | 0.90 | | | 创 | | | | | | | 600797 | 浙大网 | 2.21 | 12.71 | 10.09 | 10.18 | 0.86 | | | 新 | | | | | | | 603931 | 格林达 | 1.26 | 2.57 | 27.21 | 27.42 | 0.78 | | 002584 | 西陇科 | 0.78 | 5.68 | 9.04 | 9.10 | 0.71 | | | 学 | | | | | | | 688593 | 新相微 | 1.50 | ...

Core Viewpoint - The blood oxygen monitor concept sector has shown a positive performance, with a 1.62% increase, ranking fifth among concept sectors in terms of growth [1][2]. Group 1: Sector Performance - As of the close on August 7, the blood oxygen monitor concept sector saw 15 stocks rise, with Jinghua Microelectronics, Aipeng Medical, and Baolait leading the gains at 14.41%, 8.45%, and 3.51% respectively [1]. - The sector experienced a net inflow of 39 million yuan from main funds, with nine stocks receiving net inflows, and six stocks exceeding 10 million yuan in net inflow [2]. Group 2: Key Stocks - Jinghua Microelectronics had the highest net inflow of main funds at 53.64 million yuan, followed by Jiuan Medical and Kangtai Medical with net inflows of 47.85 million yuan and 47.62 million yuan respectively [2][3]. - The net inflow ratios for Jinghua Microelectronics, Kangtai Medical, and Jiuan Medical were 17.04%, 11.20%, and 7.14% respectively, indicating strong investor interest [3].

Core Viewpoint - The medical device sector is experiencing a rise, with notable increases in stocks such as United Imaging Healthcare, New Industry, BGI Genomics, and Jiuan Medical, all rising over 3% [1] Group 1: Stock Performance - The ETF tracking the CSI All Share Medical Device Index has increased by approximately 3% [1] - Specific ETFs in the medical device sector have shown significant gains, with the Medical Device ETF Fund at 0.830, up 3.23%, and the Medical Device Index ETF at 0.588, up 3.16% [2] Group 2: Future Opportunities - Analysts indicate that increasing internationalization will provide more investment opportunities in the medical device sector, with several companies expected to see high growth in international business by 2025 [2] - The performance of Hong Kong's medical device stocks has been strong this year, which may positively influence the A-share market, suggesting that investment opportunities in both A-shares and Hong Kong's medical device sector will continue to emerge [2]

Core Viewpoint - Tianjin Jiuan Medical Electronics Co., Ltd. has received a long-term credit rating of AAA from United Credit Rating Co., indicating a strong ability to repay debts with a low probability of default [1] Group 1: Credit Rating Details - The credit rating report was issued by United Credit Rating Co., which conducted a comprehensive analysis of the company's operational and financial risks [1] - The AAA rating signifies that the company has an extremely strong ability to repay debts and is largely unaffected by adverse economic conditions [1] - The rating is valid from August 5, 2025, and falls under the highest category in a classification system that includes three tiers and nine levels [1]

Core Viewpoint - Jiuan Medical's stock price has experienced a slight decline, while the company anticipates significant profit growth in the upcoming half-year due to strong performance in asset management [1] Group 1: Stock Performance - As of August 6, 2025, Jiuan Medical's stock price is reported at 38.97 yuan, down 0.31% from the previous trading day [1] - The trading volume for the day reached 49,700 hands, with a total transaction amount of 193 million yuan [1] Group 2: Business Overview - Jiuan Medical's main business includes medical device manufacturing and new retail operations [1] - The new retail segment generated revenue of 6.295 million yuan in 2024, accounting for approximately 2.4% of total revenue, primarily from partnerships with Xiaomi and XPeng [1] Group 3: Financial Performance - The company has disclosed a profit forecast for the first half of 2025, expecting a net profit attributable to shareholders between 880 million and 980 million yuan, representing a year-on-year growth of 46.24% to 62.86% [1] - The growth in profits is mainly attributed to favorable performance in the asset management business [1] Group 4: Capital Flow - On August 6, 2025, the net outflow of main funds was 13.2233 million yuan, with a cumulative net outflow of 74.1832 million yuan over the past five days [1]

Core Viewpoint - The new retail business of Jiuan Medical is a small part of the company's main operations, contributing approximately 2.4% to the total revenue in 2024, which is estimated to be around 62.95 million yuan [1] Group 1 - The new retail business is relatively independent, involving decision-making by its own department [1] - The business primarily includes partnerships with Xiaomi specialty stores, Xiaomi integrated vehicle-home stores, and Xiaopeng Motors stores [1]

2025 年 8 月 7 日 根据上述评级报告中"主体长期信用等级设置及含义"的相关说明，联合资信主 体长期信用等级划分为三等九级，其中AAA为最高主体信用级别。该等级的含义为 "偿还债务的能力极强，基本不受不利经济环境的影响，违约概率极低"。 特此公告。 天津九安医疗电子股份有限公司董事会 证券代码：002432 证券简称：九安医疗 公告编号：2025-053 天津九安医疗电子股份有限公司 关于主体信用评级结果的自愿性信息披露公告 本公司及董事会全体成员保证信息披露的内容真实、准确和完整， 没有虚假记载、误导性陈述或重大遗漏。 天津九安医疗电子股份有限公司（以下简称"公司"）委托信用评级机构联合资 信评估股份有限公司（以下简称"联合资信"）对公司信用状况进行了综合分析和评 估。日前，公司已收到联合资信出具的《天津九安医疗电子股份有限公司主体长期信 用评级报告》。联合资信基于对公司经营风险、财务风险等方面的综合分析及评估， 确定公司主体长期信用等级为AAA，评级展望为稳定，评级结果自2025年8月5日至 2026年8月4日有效。 ...